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ABSTRACT
In 2011, U.S. Markets for Heart Valve Repair and Replacement Products estimated that roughly
four million people in the United States are diagnosed with a heart valve disorder annually. And
in the following year, the American Heart Association reported that approximately 35,000 deaths
in the US were either directly or indirectly attributed to heart valve disease.
Diseases of the heart valve are degenerative in nature and therefore progressively worsen
unbeknownst to the patient until symptoms become clinically relevant. By this time, the valve is
in such poor condition that complete replacement is often the only effective treatment. Current
solutions are mechanical and bioprosthetic replacements, but each is associated with its own
inadequacies. As a result, science is now looking to the promising field of tissue engineering for
solutions to the limitations of current valve replacement options. A patient-tailored, translational
approach to heart valve replacement that is safe and effective will expectantly be the result of
efforts put into this rapidly growing area of research.
Present experiments hypothesize that the success of tissue engineered heart valves lies in the
complete recellularization of a scaffold with autologous cells prior to implantation. While
external cell seeding of the valve to avoid thrombogenicity seems to be the most obvious need,
additional focus on interstitial recellularization is necessary to obtain a truly biocompatible
replacement capable of valve remodeling and regeneration. Our short term goal is to obtain a
fully recellularized, viable valve scaffold. Thus far, infiltration of externally seeded cells into the
acellular tissue scaffold has been shown to some extent, but has led to many questions concerning
the effectiveness of those seeding methods. More specifically, there are concerns about the
characterization of the cell phenotypes found in the interstices of the cusp and their effect on the
success of the entire valve construct in vivo.

ii

The following document proposes a novel method of cell injection into acellular aortic heart
valve cusp scaffolds followed by mechanical conditioning as a prerequisite to complete valve
recellularization that will yield proper valvular interstitial cell phenotype within the construct.
Present studies have optimized the cellular injection technique, determined appropriate
conditioning methods, and shown cell retention and differentiation within the interstices of the
cusp.
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CHAPTER 1: INTRODUCTION AND BACKGROUND
1.1 The Impact of Cardiovascular (Valvular) Disease
In 2011 it was estimated that roughly four million people in the United States were diagnosed
with a heart valve disorder annually [1]. The prevalence of diseases associated with heart valves
is astounding and means good business for those in manufacturing. As “the global leader in the
science of heart valve and hemodynamic monitoring,” Edwards Lifesciences reported impressive
sales during the 2012 fiscal year so much so that they are projected their 2013 sales of Surgical
Heart Valve Therapy Devices to be more than $800 million [3].
Often the only solution when treating degeneration or calcification of heart valves is replacement
of the entire valve. Current mechanical and bioprosthetic options for heart valve replacement are
mildly satisfactory; the real promise for complete success in the future of replacements lies with
tissue engineering. There is much potential in this rapidly advancing field, and these efforts
continue to be highly funded and researched. Thanks to a surge of interest in cardiovascular tissue
engineering within recent years, major accomplishments in the field have been recorded and are
continuously being built upon by those who follow.
1.2 Relevant Anatomy
There is no doubt that the aortic valve is the most stressed tissue in the human body, completing
its open/close cycle over three billion times in a person’s lifetime [5]. With approximately 7200
liters of blood passing through its opening during the course of a single day, the aortic valve
experiences great shear flow stresses and tremendous amounts of pressure compared to the other
three valves of the heart [6]. The output that is necessary for normal functioning of the aortic
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valve is incredible; therefore the structure and tissue that the valve is composed of must be able to
withstand these mechanical requirements.
The aortic heart valve has three cusps that form semilunar attachments to the aortic root, which is
continuous with the structure known as the aortic arch [7]. The aortic annulus is the ‘ring-like’
structure that is formed circumferentially around the root as a result of the cusp attachments.
These structures all provide stabilization for the delicate and thin cusp tissue that is made mostly
of collagen, elastin, and GAGs.
The cusp is comprised of three distinct layers: the fibrosa, spongiosa, and ventricularis as seen in
figure 1. The collagen and elastin components give the cusp its load-bearing properties and
resiliency, respectively. The cusp’s ability to repeatedly be forced out of shape to open allowing
blood to flow out of the heart and then return to its closed position to prevent the backflow of
blood into the heart is facilitated by these matrix components. It is the glycosaminoglycan (GAG)
inner layer of the cusp that allows for the easy, almost frictionless changes in conformation of the
valve. This layer acts as the shock absorber to help the valve withstand the constant differences in
pressure and impact loads [5].

F
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Figure 1: Aortic Heart Valve Cusp Structure
Physiological arrangement of cusp layers [8] (left), Movat's Pentachrome
Stain of a fresh (native) cusp [9]: nuclei stain red, collagen stains yellow,
elastin stains deep purple to black, GAGs stain blue (right)
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1.3 Heart Valve Disease Etiology & Pathology
Heart valve disease can be caused by general wear of the tissue, an inflammatory response that is
initiated by cells in the area, bacterial infections, congenital defects, or other idiopathic origins.
When analyzing the stresses experienced by the aortic valve, general wear of the valve seems to
be an obvious cause of degeneration, especially as the world population is living longer. It is also
understood that the flow of blood through the valve can cause micro-tears in the tissue; these tears
trigger an inflammatory response by the native valvular cells. Valve destruction can also be
caused by severe cases of rheumatic disease; endocarditis (inflammation of the endocardium) is
the result and it leads to scarring and damage of the valve leaflets, once again initiating an
inflammatory response. This particular cause is overwhelmingly prevalent in developing
countries and indigenous groups within the developed world [10]. Many of the other causes of
heart valve disease and degeneration are not fully understood, but solutions must be ready to
combat them nonetheless.
Heart valve disease causes the failure of various mechanisms of the valve that must be retained in
order to provide efficient function. Two of the most prevalent malfunctions are insufficiency (also
referred to as regurgitation) and stenosis. Regurgitation is described as the improper closing of
the valve which then causes blood to flow backwards through the aortic valve and back into the
heart. Stenosis is classified as the hardening of the valve due to calcium build-up (calcification).
These defects in the function of the aortic valve can be the cause of other pathologies such as left
ventricular hypertrophy. This condition of the heart develops due to decreasing insufficiency in
valve function. The heart must compensate for this decrease in cardiac output by pumping harder
causing the left ventricle to pump harder and therefore increase in size (like any muscle would
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when it is over worked). Eventually, if left undiagnosed and untreated, this series of events will
lead to heart failure and death [11].
1.4 Current Treatments
As previously mentioned, by the time a patient begins noticing symptoms of valve deficiency it is
after the valve has already undergone major degenerative processes leaving it inadequate to
satisfy the great requirements of the heart’s total cardiac output. For any pathology that might be
present there are no effective drug treatments that can be used [5]. In most cases, alternative
measures are not even considered; doctors opt for the patient to receive a valve replacement. As
one of the short-term measures that can be used to temporarily relieve the symptoms of valve
disease, the doctor may suggest balloon valvuloplasty. This procedure is typically regarded as a
bridge-to-aortic valve replacement and not an end point treatment for any patient.
A revolutionary new method of heart valve replacement is gaining fast support among all those in
the medical field. The technique is called Transcatheter Aortic Valve Replacement or TAVR. The
procedure is innovative because it employs a minimally invasive approach to the replacement of a
large heart structure. Catheterization is used to insert the non-expanded valve into the femoral
artery where it is then maneuvered through the vasculature until finally reaching the opening of
the aortic valve. The replacement valve is forced through the pathologically stenosed valve and
then deployed by balloon expansion of the outer stent covering. The expansion of the stent forces
open the stenotic valve, the new valve then secures itself in place by relying on the hard calcium
deposits to act as anchors. The patient does not need to be put on heart-lung bypass in order to
replace the valve. (Note: There is also another method to performing this surgery that is referred
to as transapical, meaning through the apex of the heart.) Currently though, TAVR is only
considered for those patients who are deemed a ‘high-risk’ for surgery and for patients with
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calcific stenosis. Other valve pathologies would not provide the solid anchoring that is present on
the calcified valve [7].
The most widely used treatment option for heart valve disease is still an Aortic Valve
Replacement (AVR). This involves the complete removal of the pathologic valve and
replacement with the new valve. As discussed previously, left ventricular hypertrophy is a result
of valvular disease; after replacement of the dysfunctional valve the tissue can actually revert
back to a physiologically appropriate mass. This is one of the most significant and obvious signs
of effective treatment [5]. Following a valve replacement most patients notice quick
improvements on their quality of life.
After a patient has been diagnosed with severe heart valve disease and has been approved for
AVR it then becomes a discussion of what type of valve will be used. There are mechanical and
bioprosthetic options that are currently on the market. No matter which valve option a
patient/doctor chooses there is about a 10-15 year range that the valve is guaranteed to last. The
goal of all major heart valve manufacturers is to improve the long-term durability of the valves so
that patients would not have to undergo several surgeries throughout their lifetime [12].
1.4.1 Mechanical Heart Valve Replacements
The first designs of replacement heart
valves were for mechanical models, with
major breakthroughs occurring in the
1950’s to 60’s; researchers made many
developments in the field of science and
engineering during this time and applied

Figure 2: Mechanical Heart Valves
Starr-Edwards Silastic Ball Valve (left) and
St. Jude Medical Masters HP Valve (right).
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them effectively to the clinical need for heart solutions. The ball-in-cage design prevailed for
many years until the tilting disc’s emergence. Eventually the pyrolytic carbon bileaflet valve was
designed in the 1970’s and became the ‘gold standard’ for mechanical valve replacement. Since
St. Jude Medical introduced this pyrolytic carbon valve much of the innovation in this area has
come to a halt; only minor features of the mechanical valves have evolved over the last forty
years.
Some of the early challenges with mechanical valves were related to closing load, material
fatigue, and cavitation. Transvalvular pressure produced variations in the load experienced by the
valve which lead to “impact wear” and “friction wear.” These two forces worked to weaken the
structure of the valve. Also, like any device, material fatigue played a large role in the valve’s
success or failure. This obstacle was overcome with the evolution of materials; once the switch
from metal to pyrolytic carbon was made this seemed to solve fatigue issues. The third most
significant failure mode was cavitation, which is characterized by the formation of microbubbles
in the blood. The microbubbles can, over time, cause pitting and erosion on the surface of the
valve. This problem was solved during the 1970’s and 80’s with small engineering design
changes; since then, no reports of failure of the mechanical valves have been reported around
those modes of mechanical failure.
Although mechanical valves are the most durable solution (typically said to last for 20-30 years)
for heart valve replacements there is still one very large issue that has yet to be completely
avoided. The thrombogenicity of the artificial surface is cause for much concern. Not only are the
devices non-biological, they also introduce turbulent flow regimes in the flow of blood. The
turbulence can activate platelets which in turn initiate the formation of thrombi. To prevent this
process from occurring, patients are put on life-long anticoagulant therapy. This involves the
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administration of Warfarin, a drug that minimizes the risk of thrombus formation on the valve
surface. Because this drug decreases the blood’s ability to coagulate on the valve it also means
that it prevents coagulation systemically leaving the patient vulnerable to major bleeding events.
This reliance upon the close monitoring of a potentially dangerous and expensive drug therapy is
the main factor that has kept mechanical valve replacement out of developing countries [13].
1.4.2 Bioprosthetic Heart Valve Replacements
The

solution

to

the

possibility

of

thrombogenicity with mechanical valves
was

solved

with

the

advent

of

bioprosthetic valve (BPV) technology.
These valves are made from either porcine
aortic valves or bovine pericardium that
has been chemically fixed, cross-linking

Figure 3:
Bioprosthetic Heart Valves
Medtronic Freestyle Tissue Valve (left) and
Edwards Lifesciences Perimount Magna
(right)

the tissue and masking the antigens present in the xenogeneic materials. There is much debate
between the tissue options and their design features, but thus far most options have shown
comparable results. Although patients do not have to be on any drug therapy for proper
functioning of the bioprosthetic valve, their longevity is questionable due to other degenerative
processes, such as calcification and general wear and tear [13]. BPVs are predicted to last 10-15
years which is a much lower expectation than that of the mechanical valve [14].
The xenogeneic tissues are fixed with a dialdehyde known as glutaraldehyde. This process was
thought to completely cross-link molecules of the ECM rendering the tissue anti-thrombogenic
and inhibiting calcification. This however, was not necessarily the case because BPVs were
shown to be highly calcified upon explantation and the presence of inflammatory cells was seen
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on not only the surface of the valve but also infiltrating into the tissue. Some of the issues with
inflammation may be due to the tissue still eliciting an immunogenic response by the host. During
the fixation process, if there is insufficient masking of the receptors or glycoproteins in the tissue
the components would inevitably cause immune response. In more recent years it has been
determined that higher concentrations of glutaraldehyde can be used to come as close to ensuring
a complete cross-linking as possible. Researchers then looked into the effects of the higher
concentration of glutaraldehyde used. The numerous unbound glutaraldehyde molecules that were
present needed to be extracted because of their tendency to be pro-calcific. By removing these
free dialdehydes the tissue was made available for the formation of an endothelial layer to
flourish on the surface of the valve and calcification initiation was delayed [13].
The processing of the valves needed to be assessed to find an answer concerning durability after
the tissue was fixed. The cross-linking of the tissue obviously had an effect on the overall
strength and mechanical properties of the valve; the valve must rely purely on the integrity of the
ECM components with no active remodeling occurring when there is valve damage or
degradation [14]. When the glutaraldehyde cross-links the tissue, the GAG-rich spongiosa layer
of the cusp loses its ability to reduce the stress throughout the cusp during the open/close cycle.
With this layer virtually non-functional, the valve begins to wear at a faster rate. The annulus of
the valve was also affected by fixation because it made the tissue much more ridge. The annulus
is supposed to be able to dilate as the heart pumps and the valve opens and closes. After the tissue
in the annulus is cross-linked it loses most of its ability to function properly causing more stress
on the cusps that are attached to it.
In a recent Veterans Affairs Study by Mancini et al. a comparison was made of BPVs and
mechanical valves that looked specifically at mortality and reoperation rates. After 15 years,
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follow-ups were conducted and it was found that all-cause mortality was lower for the patients
implanted with the mechanical valves than the BPVs. Also, the reoperation rate was much lower
for mechanical than BPV. The data all pointed to what some had already concluded, which is that
as far as long-term durability is concerned the mechanical valve is the superior [15].
Although the mechanical valve is more durable and can be projected to last longer, the BPV is
still the best choice for those patients who cannot be put on anticoagulant regimes. This group
would include women who are pregnant or are planning to have children and those who may not
want to be put on drug therapies due to a very active lifestyle. There is a trend of patient
populations that receive certain valves, such as elderly patients (65 years and older) typically
receive BPVs because of the reduced chance for calcification, and younger patients/children
receive mechanical valves due to the decreased number of reoperations required [5].
1.5 Tissue Engineering Solutions for Heart Valve Replacements
Tissue Engineering seeks to make curative solutions for patients who are seeking long-term
treatment of disease and tissue degeneration. The constructs that are being researched and tested
are not simply there to try to compensate for the damaged tissue, the aim is create an actual living
tissue that can be implanted into a human that will, from that point on, grow and remodel. There
are five main approaches to heart valve tissue engineering which have been seen as the main
focus in more recent research: 1) forming a tissue through in vitro, bioreactor conditioning by
seeding cells on some type of biodegradable scaffold; 2) seeding cells on natural biodegradable
scaffolds; 3) implanting degradable tissues that are to be remodeled by native cells (also referred
to as guided tissue regeneration); 4) implanting a decellularized valve scaffold; 5) processes that
aim to generate tissues in vivo through native pathophysiological conditions [16].
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The focus of the current project is in approach 1 as listed above. Referencing the Tissue
Engineering Paradigm found in figure 4, the first step is to consider is the appropriate cell type
with which to seed the scaffold. Cells can either be obtained from fully differentiated sources or
stem cell populations. The possibilities for research using embryonic are limited due to
government policy, ethical debates, and social stigmas. This is why investigation into alternative
sources has led to great promise in adult stem cells. Several of the cell sources that are promising
are vascular-derived cells, bone marrow-derived cells, umbilical cord-derived cells, and adiposederived stem cells [17]. Most of these cell sources have been shown to differentiate into many
cell types, making them pluripotent and useful for the application of tissue engineering.
Next is the need to develop an appropriate scaffold that will support either cells seeded externally
and internally or cells that infiltrate from the patient’s surrounding native tissues. The scaffold
must also be able to perform mechanically in order to withstand the tremendous number of cycles
that it is to be put through once implanted into the body. Many different types of scaffolds have
been researched and tested, including, allogeneic (human) or xenogeneic (animal) tissues. These
are constructs made up of ECM components or are polymer-based structures. When using human
and animal tissues, a process called decellularization is employed to remove the native cells from
the valve. This is a process that involves a series of detergent washes that ‘clean out’ the cells,
leaving only the ECM components (i.e. collagen, elastin, laminin, etc.). These techniques must be
able to completely remove all immunogenic materials, and it must also be reproducible.
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Figure 4: Tissue Engineering
Paradigm- Begin by collection
of lipoaspirate from autologous
adipose tissue source. Isolate
and expand adipose-derived
stem cells. Next an aortic heart
valve is harvested from porcine
model and decellularized in
order to obtain an acellular
scaffold. Cells are then seeded
externally and internally to
obtain
a
recellularizaed
construct. Conditioning in the
bioreactor system is the final
step prior to implantation of the
tissue engineered heart valve in
the patient.
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In regards to decellularization, initial data collected by Cryolife, Inc. during in vivo animal
studies was very promising; the studies were performed using the SynergraftTM tissue engineered
heart valve. The scaffolds were decellularized porcine aortic heart valves that were implanted into
sheep in the pulmonary valve position for 150 days. When the valves were explanted the
researchers observed great host-cell infiltration; valves were repopulated by fibroblast-like cells.
They also saw that there was no increase in the calcium content of the valve afterwards. The
research proceeded to clinical trials based on their promising data. Four of the Synergraft TM
valves were implanted into children in the pulmonary position. All seemed well at first, the
surgery went well and recovery was typical, but after six weeks the first patient died due to
sudden cardiac arrest. The second patient died one year post-op, again due to sudden cardiac
arrest. The third patient died within the 7th day of implantation due to the rupture of the graft. And
lastly, the fourth patient was ordered to have the valve explanted after only two days of
implantation. Upon review of the explanted valves it was found that the tissues showed extreme
amounts of inflammation and the cusps were practically non-existent [18].
It was later concluded that the valves had not been completely decellularized; there were porcine
cells still present within the scaffold. This study cast a dark shadow over tissue engineering that is
still seen today. It did, however, shed light on areas that needed to be improved. Standards need
to be established in which a valve can be said to be 100% decellularized so that catastrophic
failures like those in this study never happen again. Also, this study showed that not all animal
models are applicable and appropriate to model in vivo conditions of a human, so we must also
work to discover the best animals for implantation.
The final stage in the tissue engineering paradigm before implantation in the patient is the
conditioning of the tissue construct in a bioreactor. Such conditioning devices can be seen
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throughout cardiovascular research; systems have been used for vascular grafts, myocardial
replacement tissues, and heart valves. The use of bioreactor tissue conditioning has been shown to
aid in the development of mechanical strength within the construct and modulate cellular function
[19]. Refer to section 2.5 for more on mechanotransduction during pre-conditioning of valve
constructs seeded with cells.
Moving forward, many realize that innovation in most areas of tissue engineering is coming from
academia and start-up companies [13]. The valves that are currently available for patient
implantation are ‘just OK,’ not great. It is tissue engineering that offers truly innovative and
revolutionary solutions for heart valve replacement. There are challenges (reference Appendix A)
that will arise from clinical translation of heart valve tissue engineering, but many researchers
have already begun the process of directing their research toward combating them.
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CHAPTER 2: HEART VALVE TISSUE ENGINEERING, INTERSTITIAL SEEDING,
AND CELLS
2.1 Heart Valve Tissue Engineering: A Shift in Focus
Heart valve tissue engineering solutions have seen a shift to putting more of an emphasis on
pediatric applications [16, 19-24]. This may be the first clinical application in which tissue
engineering replacements are introduced into patients due to the fact that it is the younger
population who would benefit the most from a construct that is able to grow and remodel as they
age. Current mechanical and bioprosthetic replacements are assumed to be sufficient for the aging
population, but neither of these options is reasonable for use in children who would quickly
outgrow them. In preparation for clinical translation of tissue engineered solutions researchers are
attempting to shift their research toward materials and methods that would be more easily
transitioned to use in patients (from section 1.5 and Appendix A).
Highlighting some of these proactive steps toward clinical translation, more focus has been
placed on the concerns surrounding patient variation and an effort has been made to determine
ways in which tissue engineering solutions can adapt to, detect, and combat these differences.
From patient-to-patient, large variations are seen in the way each person responds to wound
healing and tissue remodeling. The overall success of a replacement relies on the ability of the
patient’s own biological processes to aid in the healing and remodeling of the tissue. Research
into methods of controlling this variability will be fruitful toward the acceptance of the use of
tissue engineered replacements and proof of efficacy amongst all patient populations.
The next step toward clinical translation is addressing the set of safety, efficacy, and quality
control standards by which tissue engineered devices will need to be tested and validated.
Beginning with safety studies performed in vitro, a standardized bioreactor testing system will
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need to be established which will be a large undertaking in itself. The tissue engineered solutions
will also need to undergo performance and functional testing protocols that need to be created and
agreed upon. And lastly, in vivo preclinical studies need to be designed in such a way that they
address actual human response to the device. Currently ovine and porcine models are considered
the most robust in vivo model for heart valve testing. Sheep are generally helpful to use in
calcification prediction and pigs in thrombogenicity potential [20]. But neither model is reliable
for comparison in immunological response of the host. Also, the ovine cardiovascular system is
able to heal more quickly and completely than a human’s so it is difficult to understand the
wound healing process of the replacement valve fully [16]. Researchers however, do not see these
concerns and challenges as a deterrent to continuing progress toward the end goal of developing a
tissue engineered replacement that will undoubtedly revolutionize modern medicine.
2.2 Previous Interstitial Cellular Seeding/Infiltration Techniques and Outcomes
Many methods for cell seeding have been tested and reported in literature. One of the more
commonly seen methods uses decellularized valve scaffolds that are externally seeded with cells
and dynamically conditioned in vitro with the hope of observing cell infiltration. In SchenkeLayland et al., cells collected from ovine sources (endothelial cells and myofibroblasts) were
externally seeded onto decellularized porcine pulmonary valves that were then subjected to a
maximum of 16 days in a pulsatile bioreactor system. Cell infiltration into the cusps was observed
after the conditioning period. It would seem as though the myofibroblasts (MF) had in fact been
able to migrate into the cusp and repopulate the structure. Since the MF was used to seed, the
cells in the interstices stained positively for both Vimentin and α-SMA [24-25]. When discussing
the results of the study the researchers admitted that a less invasive approach for cell isolation
was needed and that they were not sure whether or not the high levels of α-SMA were an
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indicator of positive tissue remodeling or if it would lead to the beginning of an unfavorable
pathological response.
Other groups have developed more novel techniques of infiltration. Cushing et al. reported on the
method of serum deprivation in order to repopulate an acellular scaffold. They isolated valvular
interstitial cells (VICs) from porcine aortic cusps and seeded those externally onto acellular
porcine aortic cusps. The protocol called for recurrent exposure of seeded cells to serum
deprivation (using media with 5% FBS instead of 15% FBS) [26]. Although they did observe an
‘accelerated’ cell infiltration, as opposed to infiltration when using a normal serum level, the
process was still lengthy. Infiltration began around 2 weeks, but the scaffolds were not considered
fully repopulated until 4 weeks. While the result of obtaining VIC recellularization of the cusps is
a great outcome, it is one that is not clinically relevant due to the use of an inaccessible cell
source and the time in which it took to achieve. Another note to be made is that during the 4
weeks that the study was conducted, the cusps were in no way mechanically stimulated or
dynamically conditioned.
Another novel approach to heart valve scaffold seeding is coined the “self-seeding heart valve.”
The technique developed by Jordan et al. uses antibody surface conjugation as a means to attract
circulating progenitor cells in vivo to repopulate the scaffold. The group used CD133 antibodies
that were conjugated to decellularized porcine pulmonary valves. The conjugated valves were
then transplanted into sheep in the pulmonary position and explanted after 1 and 3 months. Again,
repopulation of the cusps was observed, but expression of α-SMA was found throughout the cusp
even after 3 months of implantation [27]. They do not seem to believe that the extensive
expression of α-SMA will cause any later issues, but as described in the following section, 2.4, αSMA may not be what researchers want to see throughout their cusps. Also, no immunological
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stains were reported; the cells that are staining within the cusp structure could be macrophages or
other lymphocytes that have infiltrated.
2.3 Adipose-Derived Stem Cells
When seeding tissue engineered scaffolds for regenerative medicine the challenge of stem cell
availability can be one of the most difficult to overcome. Both scientists and clinicians are
looking for cell sources that are in line with the criteria listed by Gimble et al.: 1) can be found in
abundant quantities; 2) can be harvested by minimally invasive procedures; 3) can differentiate
along multiple cell lineage pathways in a regulatable and reproducible manner; 4) can be safely
and effectively transplanted to either an autologous or allogeneic host; 5) can be manufactured in
accordance with current Good Manufacturing Practice guidelines [28]. These requirements are
necessary in order to develop clinically translatable approaches to tissue engineering. Many cell
sources are ruled out due to very small yield from harvesting, such as bone marrow-derived
mesenchymal stem cells; out of the 6x106 cells collected it is believed that only 0.001-.01% are
actually stem cells [29]. Or they are excluded because of the invasive and painful procedures used
to obtain them. For example, bone marrow collection is an extremely painful procedure and one
that most patients would not choose if there were a better option. These and many others are
reasons in which the focus has shifted to investigation into adipose-derived stem cells (ADSCs).
They are readily available and easy to obtain through routine liposuction procedure. The process
of ADSC collection, isolation, expansion, and differentiation is displayed in figure 5. Out of
approximately 1 gram of adipose tissue 2x106 cells can be collected and 10% of those are
believed to be stem cells [29]. ADSCs are also known to differentiate into a large variety of cell
lineages, as seen in figure 5.
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Figure 5: Collection, Isolation, Expansion, and Differentiation of Adipose-Derived Stem
Cells

Lipoaspirate is first collected from the patient, and then collagenase is added in order to
enzymatically digest the tissue. Centrifugation of the infranatant isolates the stromal
vascular fraction (SVF) from the supernatant. The ADSCs can then be plated and
expanded. ADSCs have been shown to differentiate into many cell types [29].
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2.4 Valvular Interstitial Cells
Within in the last decade much has been hypothesized and/or discovered about valvular
interstitial cells (VICs) and their function within the heart valve cusps. The valvular interstitial
cell is the most prevalent cell type in the heart valve; the heart valve is also the only location in
the body in which VICs are found. They function to maintain valve structure and they aid in
repair and remodeling of the cusp microstructure. The repair function of the VIC is only initiated
after some type of trauma or exposure of the cusps to abnormal flow.
Avrum Gotlieb’s group has proposed one of the more popular opinions on VICs. They claim that
VIC phenotypes can be organized into five groups according to their function: embryonic
progenitor endothelial/mesenchymal cells, quiescent (qVIC), activated (aVIC), progenitor
(pVIC), and osteoblastic (obVIC). qVICs are the cells that are found in the adult valve that
participate in the maintenance of normal valve physiology; they are believed to maintain the
characteristic avascularity of the cusp structure by inhibiting angiogenesis. aVICs regulate
pathological responses that occur in valve disease and injury. pVICs are believed to be a

Figure 6: Valvular Interstitial Cell Phenotypes – Solid arrows depict the
transitions that are currently understood. Hatched arrows depict possible
transitions for which there is currently no solid evidence [28].
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population of cells that play an important role in valve repair. obVICs are the cells that are
present in calcific valve pathologies; they regulate chondrogenesis and osteogenesis [28].
“The pathogenesis of cardiac valve disease correlates with the emergence of muscle-like
fibroblasts (myofibroblasts).” This quote from Walker et al. uses the word myofibroblast, but in
accordance with the previous description of VIC phenotypes, this cell type can also be termed an
aVIC (activated VIC). In all pathologies of the heart valve, for example, degeneration and
calcification, aVICs are found throughout the tissue. And it is α-SMA staining that is the
hallmark marker to confirm aVIC presence. The results from studies described in section 2.2 and
many others that report extensive staining of α-SMA in their tissue engineered valves are
worrisome due to the pathological consequences that could and would be sure to follow with
prolonged expression of α-SMA. Many researchers in heart valve tissue engineering support the
understanding that activated VICs are not ideal to have within a cusp that is implanted within a
patient [30-37].
The status of VIC activation is dependent upon the biochemical and biophysical cues within their
microenvironment [36]. In vitro, molecules such as TGF-β have been shown to induce and
significantly increase VIC expression of α-SMA and other aVIC markers. A synergistic
relationship in cell expression of α-SMA is seen when TGF-β exposure is coupled with
mechanical stress on the cells [37]. In vivo, TGF-β is secreted by VICs in response to injury and
inflammation of the tissue and therefor leads to the increased presence of aVICs. This mechanism
is important when considering therapies that can decrease or even reverse pathological activation
of valvular disease. It is the goal of tissue engineering to design around these two parameters to
provide conditioning and molecular signaling that is similar to native cusps in order to attain a
valve that is ready for remodeling and regeneration in vivo.
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2.5 Mechanotransduction and the Effect of ECM on Stem Cell Differentiation
The use of bioreactor systems to pre-condition cell-seeded constructs is typically seen in most
tissue engineering approaches. These systems are used to expose seeded cells to varying
mechanical forces to induce cellular mechanotransduction. When looking specifically at heart
valves and the valvular interstitial cells within the tissue it is important to mimic the unique
mechanical environment at this site. Several studies that aimed to recreate the native heart valve
tissue mechanics have confirmed that applying cyclical mechanical stimulation of cells leads to
higher rates of cell proliferation, enhanced production of ECM components, and differentiation of
stem cells to a desired phenotype in vitro [38-40].
Mechanical stimulation combined with the presence of extracellular matrix components, such as
collagen and elastin, encourages a synergistic relationship on improved stem cell differentiation
and scaffold remodeling. Following the decellularization process ECM components and specific
binding sites are retained. These features of the scaffold allow for better cell adhesion through
integrin attachment and signaling to encourage phenotypic changes. The acellular scaffold is able
to provide a unique niche in which cells can attach, differentiate, proliferate, and lay down
extracellular matrix. It is therefore the ideal biomaterial to use for tissue engineered heart valves
due to its ability to induce stem cell differentiation and remodeling of the structure [41].
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CHAPTER 3: MATERIALS AND METHODS
3.1 Materials
Tissue Decellularization
0.05M NaOH, (0.05% SDS-sodium dodecyl sulfate, 0.5% Triton X-100, 0.5% NaDeoxycholate, and 0.2% EDTA, in 10mM TRIS, at pH 7.5) (all chemicals were of the
highest purity available and obtained from Sigma-Aldrich Corp., Lakewood, NJ)
DNase – deoxyribonuclease (Sigma, Steinhelm, Germany)
RNase – ribonuclease (Thermo Fisher Scientific, Waltham, MA)
High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl glucose, PGG) was
a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium
(www.omnichem.be)
Neutralization
Neutralization Solution (DMEM, 50% FBS, 1%PSA)
DMEM - Dulbecco’s Modification of Eagle’s Medium (Corning cellgro®, Manassas,
VA)
FBS - Fetal Bovine Serum (Atlanta Biological, Atlanta, GA)
PSA - Penicillin, Streptomycin, Amphotericin B (Corning cellgro®, Manassas, VA)
Cell Culture
hADSC – human adipose-derived stem cell (Invitrogen, Carlsbad, CA)
Complete MesenPRO RSTM Medium: MesenPRO RSTM Basal Medium and MesenPRO
RSTM Growth Supplement (Life TechnologiesTM, Carlsbad, CA)
Trypsin EDTA (Corning cellgro®, Manassas, VA)
Cell Scepter (EMD Millipore, Darmstadt, Germany)
Interstitial Cellular Seeding
Seeding Solution (DMEM, 10% FBS, and 1% PSA)
33G needles (Hamilton Company, Reno, NV)
Air pump (Gast Manufacturing, Inc., Benton Harbor, MI)
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Conditioning
DMEM, 10% FBS, and 1% PSA
Rotator (developed by Richard Pascal, manufactured by Clemson University Machining
and Technical Services)
Bioreactor (developed by Lee Sierad, manufactured by Clemson University Machining
and Technical Services)
Histology
4% paraformaldehyde (Electron Microscopy Services, Hatfield, PA)
Hematoxylin & Eosin (H&E) Stain (Thermo Fisher Scientific, Waltham, MA)
DAPI (4’-6-Diamidino-2-phenylindole) Nucleic Acid Stain (Life TechnologiesTM,
Carlsbad, CA) and the Vectashield HardSetTM Mounting Medium with DAPI (Vector
Laboratories, Inc., Burlingame, CA)
Movat’s Pentachrome (Poly Scientific R&D Corp., Bay Shore, NY)
Immunohistochemistry (IHC) antibodies: α-SMA #ab5694, Vimentin #ab92547, prolyl4-hydroxylase (P4HA3) #ab101657 (Abcam, Cambridge, MA)
Vectastain Elite Kit and ABC diaminobenzidine tetrahydrocholoride peroxidase substrate
kit (Vector Laboratories, Burlingame, CA)
Microscope/Camera (Zeiss Axiovert 40CFL microscope using AxioVision Release 4.6.3
digital imaging software, Carl Zeiss MicroImaging, Inc. Thornwood, NY)
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3.2 Methods Overview
Figure 7: Methods Overview

Valve Collection
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and Quality Control

Interstitial
Cell Seeding

Dynamic
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Cell Analysis
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3.3 Experimental Methods
3.3.1 Valve Collection and Cleaning
Aortic valves were harvested from porcine hearts donated by Snow Creek Meat Processing Plant.
The aortic valve was dissected out of the heart in such a way as to maintain excess tissue above
and below the annulus of the valve. Tissue on the ventricular side of the valve (portions of the
mitral valve and surrounding muscle) was needed in order to secure the valve within mounting
rings. A large portion of the ascending aorta was also retained for securement in decellularization
and conditioning processes. It is important to note that this additional tissue would also serve as a
clinical means of suturing the tissue engineered valve into the patient. To prepare the valve for
decellularization the loose fascia was removed from around the outside of the aorta and the
excess tissue on the ventricular side was thinned to approximately 1.5-3 mm thickness. The
coronaries were then isolated from the fat and aorta, and ligated with sutures. After trimming and
ligation, the valves were rinsed in ddH2O and placed into metal mounting rings, as seen in figure
8. These mounting rings are compatible with all devices used for decellularization and
conditioning, enabling easy transfer from one system to the other. The valves were stored in
ddH2O at +4oC in the refrigerator to begin the decellularization process by inducing cell
hypotonic shock.
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Figure 8: Valve Mounting

A. Excess tissue on the ventricular portion of the valve was spread over plastic
inner ring. It was important to center the opening of the valve in the middle of the
ring; this would ensure space for the leaflets to open and close properly; B. view
from aortic side of the valve; C. plastic ring was secured between the metal base
and tightening ring; D. view from the ventricular side showing proper positioning
of the valve opening; E. aorta outer legs and aortic inner tube were placed around
the aorta extending from the valve; F. final secured mounting structure, the aorta
was then sutured to the plastic inner tube to provide stability to the structure.
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3.3.2 Valve Decellularization
Decellularization protocol followed that of previously published, Sierad et al. [42]. Briefly, after
valves were stored in ddH2O for at least 22 hours the rest of the decellularization process began
with 2 hour incubation in NaOH to relax the extracellular matrix and prime the matrix for cell
removal. Followed by three 48 hour washes in decellularization solution, 24 hours in
DNase/RNase solution to remove nucleic acids, 2 hours in peracetic acid to sterilize the valves
(after this point all steps were done in sterile conditions with sterile filtered solutions and sterile
tools), 20 hours in PGG (penta-galloyl glucose) to crosslink the scaffold, and finally stored in
PBS. All solution changes during the decellularization were separated by adequate rinsing and
incubation in ddH2O, EtOH, or PBS. During these solution steps, rinses, and incubations the
valves remained moving in solution on an orbital shaker plate.
3.3.3 hADSC Culture and Subculture
To thaw and establish hADSCs, cells were removed from cryopreservation in liquid nitrogen,
quickly warmed and placed into fresh, warm Complete MesenPRO RSTM Medium. Cells were
then plated onto a T-175 flask at a density of about 5000 cells per cm2. After overnight incubation
at 37oC and 5% CO2 media was replaced. Media change, using Complete MesenPRO RSTM
Medium, occurred every 3-4 days to maintain culture and promote proliferation.
To subculture hADSCs, media was aspirated from the flask. The surface was rinsed with PBS,
and then aspirated. Trypsin EDTA that was warmed to 37oC was added (at approximately 0.5 mL
per 10 cm2) to detach the cells from the flask. Incubation at 37oC in Trypsin EDTA lasted for
approximately 5 minutes or until majority of the cells had detached. When cells were detached
Complete MesenPRO Medium was added (approximately 1.5x the volume of Trypsin EDTA
used). The cell suspension was transferred to a 50 mL conical tube and centrifuged at 210 x g for
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5 minutes to form the stromal vascular fracture (cell pellet). Complete MesenPRO RSTM
Medium/Trypsin EDTA mixture was aspirated out of the conical, leaving the pellet intact.
Seeding solution was then used to resuspend the cell pellet for counting. The cell scepter was
used to count the cells, from which the total number of cells was calculated. Cells were
resuspended at the desired density (about 5000 cells per cm2) and plated. MesenPRO RSTM
Medium was replaced every 3-4 days.
3.3.4 Neutralization
After the valves were decellularized and PGG-fixed, they remained in sterile 1x PBS until use.
Before the valves could be seeded they underwent neutralization incubation. Valves were
incubated in rotating chambers filled with approximately 120mL of neutralization solution for 1222 hours at 37oC in the incubator. This step was used to neutralize any unbound PGG and
enhance the valve scaffold by introducing growth factors prior to seeding.
3.3.5 Interstitial Cell Seeding
3.3.5.1 Study 1: Injection Testing with Carbon Nanoparticles
Initial injection testing was performed using carbon nanoparticles suspended in DMEM. The
carbon first needed to be passivated; dry carbon particles were added to PBS , vortexed several
times, bath sonicated for 5 minutes, then centrifuged at 1500 rpm for 5 minutes. A pellet of
carbon was formed at the tip of the conical, PBS was removed by vacuum, and pellet was
resuspended in FBS by vortexing several times. Particles were left in FBS overnight at room
temperature. The following day the solution was centrifuged at 1500 rpm for 5 minutes. Pellet of
carbon was formed, FBS removed by vacuum, pellet resuspended in DMEM by vortexing several
times. This final injection solution was stored in +4oC refrigerator until use.
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Carbon solution was injected using a 30 GA needle either directly into the cusp or indirectly into
the cusp through the aortic wall. The injection of carbon was an effective method to visualize the
way in which cells would fill the cusp. Figure 9 shows both macro and micro images of the
carbon within the scaffold. It was noted that the carbon did not spread in the cusp much farther
than the injection site. Alternate methods of injection were proposed to obtain more complete
filling of the cusp, but it was really the separation of the cusp layers that would facilitate the
spreading of solution throughout the structure.
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Figure 9: Carbon Particle Injection

A

B

A. Decellularized porcine aortic heart valve injected with
carbon nanoparticles (black seen within the cusp structure)
both directly and indirectly; B. 10x image of carbon particles
(black particulates within cusp structure) within the
decellularized cusp structure Movat’s stain: nuclei stain bright
red, collagen stains yellow, elastin stains deep purple to black
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3.3.5.2 Study 2: Air Pre-injection Testing
Pre-injection of air was first attempted using a syringe filled with air, but the pressure generated
by hand was not sufficient to achieve desired separation of cusp layers. An air pump was tested
and found that a pressure of 15-20 psi would provide adequate expansion of the cusps. The
moment that the tip of the needle penetrated the top layer of the cusp the structure expanded and
separated the cusp layers creating a void in which cell suspension could then be injected. Figure
10 clearly displays the pockets within the cusp that were created. The base of the cusp was seen
to yield the most complete air expansion, and therefore the most complete cell seeding.

31

Figure 10: Air Pre-Injection

A. 2.5x image of the base of the cusp structure; pre-injection of air into the base of the
cusp inflated and created pockets within the scaffold; B. 10x image displaying cells that
had been injected after air inflation; C. 10x image displaying size of defect created in the
scaffold. H&E stain: nuclei stain purple, ECM components stain pink.

32

3.3.5.3 Study 3: Injection Protocol
All sterile materials were prepared prior to seeding in either Ethylene Oxide or Autoclave at
121oC. Rotating chambers and bioreactors were assembled before any cell work occurred.
Desired amount of cells (about 4 million per cusp) were passaged and stored in 50 mL conical at
a concentration of about 8 million cells per mL of seeding solution in the incubator until use.
Valves that were designated as those that would undergo bioreactor conditioning were secured in
mounting rings and the aorta sutured to the aorta inner tube. The valves that were designated as
those that would undergo rotational conditioning were only secured in the mounting rings. Cells
were removed from the incubator and mixed by inverting the conical. Syringes were pre-loaded
with 1 mL of cell suspension (approximately ½ mL per cusp, 4 million cells). The pictures in
figure 11 illustrate the following injection processes. Air pump and 33 GA x 1 ¼ inch needle
were used to inflate the base and free edge of the cusp with approximately 1-2mL of sterile air. A
33 GA x 1 ¼ inch needle was then attached to the pre-loaded syringe and cell suspension was
injected into inflated portions of the cusp (about 0.25 mL per injection site). This same injection
procedure was repeated for each cusp in each valve. Specified valves were either transferred into
the bioreactor or rotator for conditioning. The bioreactor was filled with about 700 mL of media
and the rotating chamber filled with about 120 mL of media. Bioreactor pressures and rotator
speeds were monitored daily and media was changed every 3-5 days as needed.
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Figure 11: Injection Procedure Pictorial

A. Collected all materials for air injection; B. small bulb pipette and valve that was
secured in metal mounting rings; C. view when looking down the aorta into the
valve; D. the bulb pipette was inserted from this side of the aorta in such a manner
that it filled the cusp; E. once the pipette tip was inside of the cusp, the valve was
reversed so that the observer was looking at the valve from the ventricular side; F.
the cusp was then stabilized and stretched outward, gaining better access for
injection; G. valve and pipette were all be held within one hand, with the other
kept free to perform the injection; H. pump was attached to a sterile filter and
tubing; I. pressure was maintained between 15 and 20psi
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J. Close up of stretched cusp; K. needle attached to the tubing was held in opposite
hand; L. needle tip was carefully advanced into cusp at the base (where the cusp
meets the aortic wall; M. when cusp structure began to inflate the needle was kept
in until desired inflation was achieved and then removed; N. needle was then
detached from the tubing by its luer connection; O. with the valve still in one hand,
the 1mL syringe was filled with cell suspension; P. filling of the syringe was done
with one hand, the plunger pulled upwards between thumb and forefinger; Q.
approximately 0.5mL was used per cusp (4 million cells), one syringe was
sufficient for two cusps; R. needle was then reattached to the syringe luer
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S. Gripped syringe with one finger on the end of the plunger and the others secured
around the body; T. cell suspension was administered at cusp inflation site; U.
needle tip was carefully advanced into cusp; V. once the needle was in place the
plunger was depressed, administering cell suspension into the cusp; W. continued
to administer suspension until the solution filled the entire inflated base; X.
approximately 0.25-0.5mL of cell suspension per injection site was used; Y. needle
tip was then carefully inserted into the tip portion of the cusp; Z. depressed plunger
to administer approximately 0.25mL of cell suspension and removed needle; AA.
Cusp was then considered seeded and the process repeated for each of the other
cusps
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3.3.6 Dynamic Conditioning
Bioreactor
For the first 24 hours that the valves were in the bioreactor pressure was kept at a minimum; just
enough to have slight opening and closing of the leaflets. Over the following 14 days pressure
was steadily increased to simulate pulmonic conditions (25-10 mmHg) and 65 beats per minute.
Valves were kept at these conditions for 10 more days and the study concluded after 24 total
days within the bioreactor. Media was changed every 3-4 days.
Rotator
Immediately after the valve chambers were secured in the rotator the shaker plate to which it was
attached was started at a level of 2.5 and the rotator was set to speed of 5 rpm. When looking at
the valves while rotating, movement of the cusps was observed. The speed of rotation was
increased over 10 days until 10 rpm was reached and the shaker plate was at level 4. The
remaining 14 days of the study the valves remained at these conditions, and on day 24 the study
was concluded. Media was changed every 3-4 days.

Figure 12: Rotator and Bioreactor Conditioning Systems - Rotating chamber
(developed by Richard Pascal) attached to shaker plate (left) [43]. Clemson Heart Valve
Bioreactor v1 (developed by Lee Sierad) (right) [42].
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Figure 13: Media Replacement in Rotating Chambers

A
Barb/Luer
Connector

10mL Syringe

Clave

Valve
Root

B

Vacuum
Tubing

A. Valves within seeding chambers; media change was essential for studies
beyond a 3-4 day time period; in order to remove the media, barb/luer ended
connectors were placed on claves that were secured to the lid of the chamber,
this barb was then connected to a vacuum pump which pulled the media out; to
replace media a 10mL syringe with luer connection was placed onto the second
clave that was secured to the chamber lid, then media was added; B. Removal of
media through vacuum suction.

38

Table 1: Bioreactor (Left) and Rotator (Right) Conditioning Regimes
Time [day]
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Pressure [mmHg]
10
11
12
13-15
16-18
19
20
21-22
23
23
23
23
23
23
24-25
25
25
25
25
25
25
25
25
25

Time [day]
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Speed [rpm]
5
5
5
6
6
6
7
8
8
9
10
10
10
10
10
10
10
10
10
10
10
10
10
10

Shaker
2.5
3
3
3
3
3
3
3.5
3.5
3.5
4
4
4
4
4
4
4
4
4
4
4
4
4
4

Figure 14: Bioreactor Pressure Regime
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3.3.7 Histological Analysis
Cusp tissues were dissected out of the valves and placed in 4% PFA. Processing of tissues was
then done using a Tissue Tek® Processor, followed by embedding, and sectioning (at 4um).
Orientation of the cusp sections were in the radial direction. All histological analyses were carried
out according to the product specifications. Brief descriptions of protocols and solutions have
been listed below.
Hematoxylin & Eosin Staining Procedure
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DAPI Staining Procedure

Movat’s Pentachrome Staining Procedure
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Immunohistochemistry Staining Procedure

42

3.3.8 Ovine Model In Vivo Study
Partnering with researchers and clinicians in Romania, large animal implantation of interstitially
seeded aortic heart valve constructs studies have begun. Lipoaspirate is collected from the fatty
tissue around the neck and shoulder blades of the sheep. The adipose-derived stems cells can then
be isolated and cultured. Valves are decellularized by perfusion method, fixed with PGG, and
neutralized in DMEM, FBS, PSA solution. The scaffolds are then seeded interstitially by the
injection method that is displayed in figure 11. The method was taught to several of the people
who are directly working on the project in Romania, two researchers and one clinician. These
individuals learned the cell injection technique quickly and have been able to reproduce the
process on their own. Thus far three sheep have been implanted with injection seeded aortic heart
valves within a pulmonary conduit.

Figure 15: Ovine In Vivo Study – One of the sheep that was implanted with
an interstitially seeded aortic heart valve. Visible incision and shaved areas
from where the adipose tissue was retrieved are seen.
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CHAPTER 4: RESULTS
Figure 16: Decellularization Analysis

Comparison of fresh cusp tissue (left) and decellularized cusp tissue (right). H&E (top):
nd
nuclei stain purple, ECM components stain pink. DAPI (2 from top): nuclei stain bright
rd
blue. Movat’s Pentachrome (3 from top): nuclei stain red, collagen stains yellow,
elastin stains deep purple to black, GAGs stain blue. Gross images of cusps after being
dissected out of the aortic valve structure (bottom).
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Figure 17: Cusp Immediately After Seeding, 24 Days in Bioreactor, and 24 Days in
Rotator: H&E and DAPI Staining

Comparison of seeded scaffolds over various time points; immediately after seeding (left),
24 days in bioreactor (middle), and 24 days in rotator (right). H&E (top 2 rows): nuclei
stain purple, ECM components stain pink. DAPI (bottom): nuclei stain bright blue.

Images of the cusp immediately after seeding confirm that a large bolus of cells was introduced
into the structure. From the H&E images of the cusp after 24 days in the bioreactor, there appear
to be many cells retained within the cusp, but when comparing the DAPI image of that same
location only a few cell nuclei are visible. Both the H&E and DAPI images of the cusp after 24
days in the rotator the cell population is characteristic of native (fresh) aortic heart valves.
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Figure 18: Cusp after 24 Days in the Bioreactor: H&E, Movat’s Pentachrome, and IHC
(Vimentin) Staining

Images depicting the structure of the fibrosa (top) and ventricularis (bottom) after 24 days
of bioreactor conditioning. H&E (left): nuclei stain purple, ECM components stain pink,
Movat’s Pentachrome (middle): nuclei stain bright red, collagen stains yellow, elastin
stains deep purple to black, fibroid/muscle stains red. IHC for Vimentin (right): brown
staining is positive expression counterstain with 50/50 hematoxylin.
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Figure 19: Cusp after 24 Days in the Rotator: H&E, Movat’s Pentachrome, and IHC
(Vimentin) Staining

Images depicting the structure of the ventricularis (top) and fibrosa (bottom) after 24 days
of rotator conditioning. H&E (left): nuclei stain purple, ECM components stain pink;
Movat’s Pentachrome (middle): nuclei stain bright red, collagen stains yellow, elastin
stains deep purple to black, fibroid/muscle stains red; IHC for Vimentin (right): brown
staining is positive expression, counterstain with 50/50 hematoxylin.

It was observed that the cells created some sort of matrix over the 24 day time period in vitro. The
higher magnification (40x) panel of the Movat’s Pentachrome stain displays the migration of cells
into the fibrosa
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Figure 20: Fresh Cusp: IHC for Vimentin, Prolyl-4-hydroxylase, and α-SMA

Immunohistochemistry (IHC) of fresh aortic heart valve cusps; brown staining indicates
positive expression of the marker of interest. Vimentin (left), Prolyl-4-hydroxylase
(middle), α-SMA (right).

The cells within the native (fresh) aortic heart valve cusp positively stain for Vimentin throughout
the entirety of the structure, denoting a fibroblast-like phenotype. Prolyl-4-hydroxylase (P4HA3)
would be indicative of any new collagen formation in the cusp structure; native cusps express
little to no P4HA3. As discussed in section 2.4, α-smooth muscle actin (α-SMA) is expressed by
those VICs that are considered ‘activated’; native cusps were shown to express little to no αSMA.
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Figure 21: Cusp after 24 Days in the Bioreactor: IHC for Vimentin, Prolyl-4-hydroxylase,
and α-SMA

Immunohistochemistry (IHC) of cusps after bioreactor conditioning for 24 days; brown
staining indicates positive expression of the marker of interest. Vimentin (left), Prolyl-4hydroxylase (middle), α-SMA (right).

Staining of Vimentin had an over development of the peroxidase step during staining protocol in
the mid-region of the section, but the individual cells staining positive for Vimentin can still be
distinguished due to direct comparison of DAPI images and IHC images; this comparison can be
made because serial section were taken. No expression of either P4HA3 or α-SMA was observed.
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Figure 22: Cusp after 24 Days in the Rotator: IHC for Vimentin, Prolyl-4-hydroxylase,
and α-SMA

IHC of cusps after rotational conditioning for 24 days; brown staining indicates positive
expression of the marker of interest. Vimentin (left), Prolyl-4-hydroxylase (middle), αSMA (right).

Positive expression of Vimentin is completely characteristic of that seen in native aortic heart
valve cusps. No expression of either P4HA3 or α-SMA was observed.
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CHAPTER 5: DISCUSSION
5.1 Decellularization
Histological evaluation, figure 16, showed excellent decellularization of the cusp tissue, which
was comparable to the results seen in the publication of reference for the decellularization
procedure [42]. However, this protocol is still insufficient in the complete decellularization of the
aortic wall, but much promise has been observed in a perfusion decellularization technique.
Complete decellularization is essential when looking into the clinical use of these constructs.
Catastrophic failure of the SynergraftTM valve construct was observed in the clinical study
discussed in Section 1.5, in which the patient’s extreme immune response was triggered by
inadequate decellularization of the xenogeneic scaffold [18].
Analysis on if the more robust perfusion decellularization process damages the cusp tissue will
need to be performed. The ECM structure post-decellularization must still be strong enough to
withstand cell seeding methods and physiological pressures. A decrease in the mechanical
properties of the cusps could hinder the proper seeding of cells via the suggested injection
technique, and could eventually have an impact on cell retention within the structure.
5.2 Cell Sourcing
When determining the cell source to be used in tissue engineering research it is important to
consider the clinical accessibility of obtaining those cells. Sources can be broadly grouped into
two types, those deemed unreasonable and those that are reasonable cell sources. Examples that
would be considered unreasonable include: embryonic, neonatal, and valvular interstitial cells.
Some of these sources are cause for ethical concern, but many are simply unable to be harvested
because they are cell types that either are no longer found in adults or cannot not be retrieved
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from the their location in-situ. For example, heart valves are deemed non-sacrificial tissues due to
the importance of their function, therefore autologous VICs cannot be collected for
recellularization purposes [32]. Reasonable cell sources include those that are readily available
and those that can be derived from readily available sources like induced pluripotent stem cells.
Any autologous adult cell source would be considered, including: bone marrow-derived stem
cells, endothelial cells, fibroblasts, and adipose-derived stem cells. Although bone marrowderived and induced-pluripotent are considered reasonable, sources like these and others similar
can be either very painful for the patient or potentially harmful due to methods used to induce
their stemness.
In order to satisfy the inadequacy of using clinically irrelevant cell types, the use of easily
acquired and readily available ADSCs is very promising due to their recorded ability to
differentiate into a plethora of cell lineages. Specifically they have been shown to differentiate
into fibroblast-like cells; expressing markers characteristic of valvular interstitial cells [29]. As
seen in figure 5, ADSCs are isolated from lipoaspirate that is obtained through route liposuction
procedures. Also, an abundant number of these cells can be found in relatively small amounts of
fatty tissue, reducing the amount of total tissue that needs to be collected.
5.3 Interstitial Cell Seeding Method
Several research groups have reported successful recellularization of the cusp structure within a
valve scaffold, but it is important to review the ways in which these groups have fallen short of a
clinically relevant replacement. Various processes require extensive scaffold preparation, seeding,
and conditioning protocols. When relying upon seeding approaches by cell infiltration it is the
long conditioning steps that are needed to observe any cell migration. It has even been noted that
after weeks of in vitro conditioning cell migration was not accomplished. Looking at groups that
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have published in vivo repopulation of the interstices of the cusp, they have not completely
characterized the cell type that has repopulated the structure. Many do not report on results of
inflammatory or immune response; it is important to know if the cells that are seen in the
structure are macrophages or other immune cells. Another hallmark of most in vivo data thus far
is the extensive expression of α-SMA throughout the cusp structure. Even after several months in
vivo cell expression of α-SMA persists [27], the indication of a myofibroblastic phenotype
(activated-VIC). The same is seen in the literature on in vitro conditioning resulting in α-SMA
expression [24, 25]. As discussed in Section 2.4, the persistent expression of α-SMA is correlated
with the development of valvular pathologies.
These along with many other reasons is why there is a need to develop a technique that is fast,
simple, and effective in order to obtain a clinically relevant heart valve replacement. Previous
attempts by those in this lab group to recellularize the acellular aortic heart cusp in vitro include
such techniques as, applying a charge across the tissue, chemotaxis, and infiltration of cells into
the interstices during static and dynamic culture. In testing, each of these techniques was unable
to achieve cell infiltration through the cusp tissue. This led to the investigation of cell injection
directly into the cusp structure. As this technique was attempted there was a need to create more
space between the cusp layers in order to inject a larger bolus of cells. Pre-injection of air into the
base of the cusp was necessary in order to achieve this separation of the cusp layers. It was
important to note that although this process did create voids within the cusp, the cells that were
injected were able to either partially or totally replace the area after conditioning in both the
bioreactor and rotator.
As the injection technique was optimized it was found, through both visual observation and
histological analysis that the best site for inflation and seeding of the cusp was through the
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ventricularis. Reviewing the anatomy of the cusp structure, Section 1.2, the ventricularis is a very
elastin-rich region. It was found that this region was the most functionally appropriate area to
introduce the 33 GA needle; the elastin fibers were able to provide a ‘self-sealing’ capability
when the needle was retracted. The radially aligned elastin fibers were able to stretch around the
needle as it was inserted and then relax back after its removal, in essence, recoil to close the
opening created in the cusp. In comparison, when the needle was inserted from the collagen-rich
fibrosa region of the cusp, air and cell suspension were able to escape due to the opening that the
needle made in the structure. It is not only the fact that the collagen bundles are aligned
circumferentially, but most importantly the collagen structure does not lend itself to having this
contractile, ‘self-sealing’ capability.
5.4 Dynamic Conditioning
During the process of engineering a tissue replacement there exists an overarching concept of
construct conditioning, whereby the scaffold and cellular components are subjected to
physiologically relevant conditions (i.e. temperature, pressure, nutrients, etc.) for some prescribed
time length. Those systems constructed to condition tissues are referred to as bioreactors, as
discussed in Section 1.5. The conditioning of tissue constructs as a prerequisite for implantation is
the direction that the field has heavily emphasized in order to create truly functional tissue
replacements [13, 16, 17, 19, 21, 22, 24, 25, 29-30, 32, 40]. Specifically for heart valve tissue
engineering, most bioreactor systems attempt to mimic the pulsatile flow of the beating heart. The
current work compared the conditioning of a pulsatile-flow bioreactor and a rotating system seen
in figure 12.
After valves were conditioned in either bioreactor or rotator systems for 24 days the recellularized
cusp sections resembled the structure of fresh (native) aortic heart valve cusps, and they also had
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very similar protein and enzyme marker expression/non-expression compared to fresh samples.
Overall the highest cell retention and what is believed to be cell proliferation was seen in the
cusps that were subjected to the rotational regime. As seen in figure 17, DAPI confirms that the
nuclei stained in H&E in the rotated cusp section are in fact nuclei. This same confirmation
cannot be said for the bioreactor conditioned cusp section; the DAPI shows few nuclei retained
within the cusp. There is over-staining seen in both the H&E and IHC for Vimentin of the
bioreactor conditioned cusp that can be very misleading, but this has been recognized and noted
in the analysis of the histological images.
IHC analysis suggests that the cells within the cusp of the rotated valve are qVIC-like, expressing
Vimentin strongly and little to no true staining for α-SMA and prolyl-4-hydroxylase. Direct
comparison of the image from a native cusp and the seeded/rotator conditioned cusp show few
differences (figures 20 and 22). The lack of α-SMA expression in the conditioned cusps is
encouraging because the goal is to achieve the quiescent-VIC phenotype for repopulation of the
interstices of the cusp. Referring to Gimble et al.’s description of VIC phenotype, Section 2.4, the
quiescent-VIC indicates normal, healthy interstitial cusp cells.
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CHAPTER 6: CONCLUSIONS
In the tissue engineering of fully recellularized heart valves there is a need to establish a more
clinically relevant interstitial population of cells and an improved, reproducible technique in
which to do so. The present work developed an interstitial seeding technique by injection of cells
directly into the heart valve cusp structure. The injection process was optimized and was shown
to be a teachable and reproducible method. Through the analysis and comparison of rotational
and bioreactor conditioning it was found that rotational conditioning of the recellularized valve is
a better suited technique in which to obtain an implantable construct that more closely resembles
that of a native heart valve. To support this conclusion we have shown the differentiation of
hADSCs, in vitro, into a VIC-like phenotype that is found in the native aortic heart valve.
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CHAPTER 7: RECOMMENDATIONS
7.1 Determining Cell Proliferation
The acellular aortic heart valve scaffold is believed to be a suitable micro-environment in which
seeded cells can interact and embed themselves. The structure should encourage cell proliferation
and remodeling of the scaffold. In order to determine whether or not the scaffold provides
appropriate components and signaling molecules to promote cell proliferation it would be useful
to stain histological sections for the Ki-67 Antigen. This particular nuclear protein is expressed
during all active stages of the cell cycle (G1, S, G2, and M-phases), but is not present in resting
cells (during G0 phase) [46]. Positive expression would indicate that, in fact, over the course of
the experiment cells had adapted to their micro-environment and the mechanical conditions to
which they were exposed and began proliferating. This would lead to the confirmation of an
appropriate cellular response while being conditioned in vitro.
7.2 Characterization of Material within Conditioned Cusps
It is important to completely characterize the material that was either created or built up in the
cusp structure. It is hypothesized to be cellular material from apoptotic cells that simply could not
be appropriately removed from the structure due to the absence of macrophages within the in
vitro setup. Several assays can be completed in order to determine nuclear apoptosis of cells in
the structure; those include but are not limited to: TUNEL, Annexin V, and Caspase-3. TUNEL
(terminal deoxynucleotidyl transferase dUTP nick end-labeling) indicates DNA fragmentation,
Annexin V tags cells that express phosphatidylserine on their surface, and Caspase-3 detects the
activation of caspase enzymes during apoptosis [47, 48]. Histological sections similar to those
seen in figures 18-22 need to be evaluated with the assays above.
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7.3 Injection Point Concerns
Although it has been proposed that the elastin-rich ventricularis is able to self-seal after injection,
there may be a need for a more active approach of sealing to ensure that cells will not leak out of
the cusp when the needle is removed. If this is desired, either BioGlue or some derivative, like
‘BTglue’ from Tedder et al., could be used to seal the point of injection [40]. These compounds
combine percentages of bovine serum albumin and glutaraldehyde into an adhesive that is used in
clinical practice and tissue engineering research. The adhesive could be applied directly onto the
injection site as the needle is removed from the cusp. It has also been suggested that a very fine
suture could be used to secure the holes made in the cusp during air and cellular injection. For
this approach to be applicable a dissection microscope would need to be used to visualize the
0.21mm (O.D. of needle from Hamilton Company Product Specifications) puncture that the
needle makes when inserted into the cusp. There is concern surrounding the mechanical function
of the cusp after employing either of these alternatives; would the cusp still be able to bend and
stretch as the valve opens and closes, would the adhesive stiffen the cusp, would the extra
punctures created by the suture cause too much damage, etc.
7.4 Long-Term In Vitro Studies Combining External and Interstitial Seeding Techniques with
Rotational Period Followed by Bioreactor Conditioning
The experiments performed to develop this research project were only run for a maximum of 24
days with only interstitial seeding being performed. Future studies should attempt to seed the
aortic heart valve cusps interstitially and externally then condition the construct over the course of
4-6 weeks; rotational conditioning should occur during the first 3-4 weeks (evaluating at least one
valve after this time period); followed by bioreactor conditioning for the remaining 2-3 weeks.
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The final conditioned valves would be compared to static controls, post-rotational conditioning,
and the studies performed previously.
7.5 Ovine Model In Vivo Studies
Preliminarily speaking, the cells that were seen in the valves after rotational conditioning seem to
be an appropriate representation of physiologically relevant quiescent valvular interstitial cell
type (positive for Vimentin and negative for α-SMA and P4HA3). If the hypothesis that the
excess material in the cusp is apoptotic cellular matter, then the only way to clear it out would be
to introduce the construct to a macrophage containing environment by implanting the conditioned
construct into an animal model. This in vivo model would serve to test if the interstitial cells
continue to display qVIC-like phenotype and if the cusp structure can indeed remodel under
physiological conditions. Valves would be implanted into juvenile sheep in the pulmonary
position; 6 months and one year time points would be evaluated.
7.6 Clinical Translation
Many of the current tissue engineering strategies rely on extensive seeding and conditioning
protocols that cannot be easily translated into the clinical setting. To reiterate from previous
statements, many researchers use cell types that are difficult, extremely painful, or even
impossible to harvest from a living person. A recent article on the clinical translation of
bioreactor systems into operating rooms aimed to provide patients with an autologous, partially
recellularized valve replacement within 2-3 days of harvesting cells [21]. Although the group has
not completely been able to develop all aspects of the protocol thus far; they have come up with
what seems like a reasonable procedure and timeline for tissue engineering valve replacement to
be implemented in the clinical setting.
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The technique of cell harvesting, seeding, and conditioning that is employed in this research
could be readily manipulated to provide a clinically relevant treatment for patients needing a heart
valve replacement. Within the clinic, adipose tissue can be harvested quickly and with
substantially less pain/discomfort relative to other methods of cell collection. From the
lipoaspirate collected, adipose-derived stem cells can be isolated and plated. As discussed in
section 2.3, a larger yield of stem cells is possible when using ADSCs as opposed to most other
cell sources. This is a very important aspect in obtaining a sufficient amount of cells with which
to seed the valve construct. The cells can then be seeded within the cusp through the injection
technique shown in figure 11. The seeded valve can immediately be subjected to rotational
conditioning. The cells within the valve can be maintained with simple media changes every 3-4
days. The rotating device is small and easily operated. It can also be redesigned to fit into a small
incubator so it is not an over cumbersome system. The longer the patient is able to wait for the
replacement, the longer the cells will have to secure themselves in the cusp structure, but if
necessary the construct could be implanted within several days of seeding.
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APPENDICES
Appendix A: Design criteria for tissue engineered heart valves [19]
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Appendix B: Major challenges in clinical translation of heart valve tissue engineering [16]
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